Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population

J Thromb Thrombolysis. 2021 May;51(4):902-904. doi: 10.1007/s11239-021-02435-1. Epub 2021 Apr 7.

Authors

Affiliations

¹ Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Lifebridge Health, Baltimore, MD, 21215, USA. pgurbel@lifebridgehealth.org.
² Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Lifebridge Health, Baltimore, MD, 21215, USA.
³ Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN, USA.
⁴ Inflammatory Markers Laboratory, Wichita, KS, USA.
⁵ CEDEX Laboratory, Nashua, NH, USA.
⁶ Critical Care Medicine, Sinai Hospital and Northwest Hospital, Lifebridge Health, Baltimore, MD, USA.

No abstract available

Publication types

Observational Study

MeSH terms

Anticoagulants* / administration & dosage
Anticoagulants* / pharmacokinetics
Aspirin* / administration & dosage
Aspirin* / pharmacokinetics
Biological Availability
Biomarkers, Pharmacological / blood*
Black or African American / statistics & numerical data
COVID-19 Drug Treatment*
COVID-19* / blood
COVID-19* / diagnosis
COVID-19* / physiopathology
Female
Hemostasis / drug effects
Hemostasis / physiology
Heparin* / administration & dosage
Heparin* / pharmacokinetics
Humans
Male
Middle Aged
Platelet Aggregation Inhibitors / administration & dosage
Platelet Aggregation Inhibitors / pharmacokinetics
Platelet Function Tests / methods
Platelet Function Tests / statistics & numerical data
Point-of-Care Testing / statistics & numerical data*
SARS-CoV-2
Thrombelastography / methods*
United States / epidemiology

Substances

Anticoagulants
Biomarkers, Pharmacological
Platelet Aggregation Inhibitors
Heparin
Aspirin